0-TESTO COMPLETO.pdf - Fondazione Santa Lucia

Sezione III: Attività per progetti
P16 – Buurman/HBT (HyCult biotechnology b.v.), The Netherlands – Competence:
Biotechnology of recombinant proteins, monoclonal and polyclonal
Abs. Role in the Project: Production of antagonistic huTNFR1 specific Fab and
scFv (H398 derivatives), murine TNFR1 and TNFR2 specific antagonistic/agonistic
mAbs to test in in vitro and in vivo disease models.
P17 – Olofsson/ARX (Arexis), Sweden – Competence: See Biovitrum/P21. Role
in the Project: See Biovitrum/P21.
P18 – Patel/ELL (Eisai), United Kingdom – Termination of participation at
month 24 – Competence: Small molecule drugs. Role in the Project: Development
and testing of glutamate antagonists and calcium channel blockers for
neuroprotective activity in vitro and in animal models.
P19 – Neumann/UNI-BONN (University of Bonn), Germany – Competence:
CNS innate immunity, mechanisms of axonal and neuronal damage. Role in
the Project: Studies in TREM-2/DAP12 mutant mice and TREM- 2 knockdown
mice; in vitro models for the study of microglia-axonal interactions and
evaluation of neuroprotective compounds; axonal transport; intracellular signaling
pathways; lentiviral vectors for expression of GFP-tagged synaptic and
mitochondrial genes; lentivirus-mediated RNA interference of microglia proinflammatory
genes; time lapse microscopy and confocal/2-photon laser scanning
microscopy.
P20 – Kettling/DIREVO (DIREVO Biotech AG), Germany – Termination of
participation at month 12 – Competence: TNF expression, recombinant proteins,
assay development, kinetic characterization, biophysical methods. Role
in the Project: Development of human TNF receptor selective agonists. Application
of relevant methods for their detailed characterization of biochemical
and biophysical properties. In-vivo characterization.
P21 – Olofsson/Biovitrum (previously ARX/P17) – Termination of participation
at month 24 – Competence: Molecular genetics, target validation in animal
models, pharmacotoxicology. Role in the Project: Validation of Ncf-1 in
EAE development; development of Ncf1 targeting compounds with therapeutic
efficacy in animal models of MS; bioinformatic integration: genotype-phenotype
data base integrating the results of genomic and proteomic studies
obtained in animal models.
P22 – Hermann/Celonic (Celonic), Germany – Entry at month 13 – Competence:
Recombinant protein therapeutics and mammalian expression systems.
Role in the Project: Production in mammalian systems of humanized anti-
TNFRI antibody and TNF fusion proteins.
P23 – Olofsson/RdOX (Redoxis), Sweden – Entering at month 25 – Competence:
Molecular genetics, target validation in animal models, pharmacotoxicology.
Role in the Project: Validation of Ncf-1 in EAE development; development
of Ncf1 targeting compounds with therapeutic efficacy in animal models
of MS; bioinformatic integration: genotype-phenotype data base integrating
the results of genomic and proteomic studies obtained in animal
models.
596 2009